Summary
3.41 -0.06(-1.73%)05/17/2024
Opthea Limited (OPT)
Opthea Limited (OPT)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -3.14 | -0.15 | -11.07 | 13.82 | 93.90 | -12.81 | 0.00 | -62.36 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 3.34 | |
| Open | 3.43 | |
| High | 3.45 | |
| Low | 3.34 | |
| Volume | 26,990 | |
| Change | -0.11 | |
| Change % | -3.14 | |
| Avg Volume (20 Days) | 9,562 | |
| Volume/Avg Volume (20 Days) Ratio | 2.82 | |
| 52 Week Range | 1.60 - 4.40 | |
| Price vs 52 Week High | -24.20% | |
| Price vs 52 Week Low | 108.44% | |
| Range | -2.77 | |
| Gap Up/Down | -0.13 | |
Fundamentals | ||
| Market Capitalization (Mln) | 280 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 39.77 | |
| Book Value | 3.0800 | |
| Earnings Per Share | -1.1360 | |
| EPS Estimate Current Quarter | 0.0000 | |
| EPS Estimate Next Quarter | 0.0000 | |
| EPS Estimate Current Year | 0.0000 | |
| EPS Estimate Next Year | 0.0000 | |
| Diluted EPS (TTM) | -1.1360 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -414.8403 | |
| Return on asset (TTM) | -0.2638 | |
| Return on equity (TTM) | -0.5042 | |
| Revenue TTM | 95,563 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.2880 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -333,338 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 6.7340 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.3432 | |
| Revenue Enterprise Value | 3,049.9005 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 43,875,400 | |
| Shares Float | 29,128,029 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.00 | |
| Institutions (%) | 20.67 | |
05/01 07:30 EST - globenewswire.com
Opthea Announces Upcoming Presentations at the Retina World Congress 2024
MELBOURNE, Australia and PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration, today announced that two scientific presentations on the sozinibercept (OPT-302) Phase 2 clinical trial results and ongoing Phase 3 clinical trial program will be made at the Retina World Congress (RWC), being held from May 9-12, 2024 in Fort Lauderdale, Florida. Frederic Guerard, PharmD, Chief Executive Officer (CEO) of Opthea, will participate in the Retina Unplugged panel discussion.
Opthea Announces Upcoming Presentations at the Retina World Congress 2024
MELBOURNE, Australia and PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration, today announced that two scientific presentations on the sozinibercept (OPT-302) Phase 2 clinical trial results and ongoing Phase 3 clinical trial program will be made at the Retina World Congress (RWC), being held from May 9-12, 2024 in Fort Lauderdale, Florida. Frederic Guerard, PharmD, Chief Executive Officer (CEO) of Opthea, will participate in the Retina Unplugged panel discussion.
04/25 09:00 EST - globenewswire.com
Opthea to Present at the OIS Retina Innovation Summit at ARVO
MELBOURNE, Australia and PRINCETON, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration, today announced that Dr. Frederic Guerard, Chief Executive Officer (CEO) of Opthea, will present the Company's clinical-stage pipeline, as well as its innovation agenda, at the OIS Retina Innovation Summit prior to the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting on May 4, 2024 in Seattle, Washington.
Opthea to Present at the OIS Retina Innovation Summit at ARVO
MELBOURNE, Australia and PRINCETON, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration, today announced that Dr. Frederic Guerard, Chief Executive Officer (CEO) of Opthea, will present the Company's clinical-stage pipeline, as well as its innovation agenda, at the OIS Retina Innovation Summit prior to the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting on May 4, 2024 in Seattle, Washington.
04/08 18:42 EST - globenewswire.com
Opthea Appoints John Han, PharmD, as VP Medical Affairs
MELBOURNE, Australia and PRINCETON, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment of John Han, PharmD, to the role of Vice President, Medical Affairs, effective April 9, 2024.
Opthea Appoints John Han, PharmD, as VP Medical Affairs
MELBOURNE, Australia and PRINCETON, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment of John Han, PharmD, to the role of Vice President, Medical Affairs, effective April 9, 2024.
04/04 18:34 EST - globenewswire.com
Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference
MELBOURNE, Australia and PRINCETON, N.J., April 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference and participate in one-on-one investor meetings on April 11, 2024.
Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference
MELBOURNE, Australia and PRINCETON, N.J., April 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference and participate in one-on-one investor meetings on April 11, 2024.
04/03 17:39 EST - globenewswire.com
Opthea Appoints Sujal Shah to the Board of Directors
Former CymaBay Therapeutics CEO brings extensive leadership experience to his role as a Non-Executive Director and Audit and Risk Committee Chair Former CymaBay Therapeutics CEO brings extensive leadership experience to his role as a Non-Executive Director and Audit and Risk Committee Chair
Opthea Appoints Sujal Shah to the Board of Directors
Former CymaBay Therapeutics CEO brings extensive leadership experience to his role as a Non-Executive Director and Audit and Risk Committee Chair Former CymaBay Therapeutics CEO brings extensive leadership experience to his role as a Non-Executive Director and Audit and Risk Committee Chair
04/03 09:53 EST - investorplace.com
7 Growth Stocks to Buy to Outperform the Nasdaq Index
As investors, we all aim to outperform the market. But beating the S&P 500 is a difficult task for most of us.
7 Growth Stocks to Buy to Outperform the Nasdaq Index
As investors, we all aim to outperform the market. But beating the S&P 500 is a difficult task for most of us.
03/19 06:00 EST - globenewswire.com
Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024
MELBOURNE, Australia and PRINCETON, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced it will host a virtual key opinion leader (KOL) event on Wednesday, April 3, 2024, from 10:00 to 11:30 am ET, featuring presentations from global retina experts:
Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024
MELBOURNE, Australia and PRINCETON, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced it will host a virtual key opinion leader (KOL) event on Wednesday, April 3, 2024, from 10:00 to 11:30 am ET, featuring presentations from global retina experts:
03/05 17:08 EST - globenewswire.com
Opthea to Participate in the Leerink Partners Global Biopharma Conference
MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that management will participate in one-on-one investor meetings at the Leerink Partners Global Biopharma Conference being held in Miami, Florida on March 11-13, 2024.
Opthea to Participate in the Leerink Partners Global Biopharma Conference
MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that management will participate in one-on-one investor meetings at the Leerink Partners Global Biopharma Conference being held in Miami, Florida on March 11-13, 2024.
02/28 17:55 EST - globenewswire.com
Opthea Reports Half-Year Financial Results and Business Updates
Enrollment completion of sozinibercept Phase 3 program for wet AMD expected in calendar year (CY) Q2 2024 with top-line data mid-CY 2025
Opthea Reports Half-Year Financial Results and Business Updates
Enrollment completion of sozinibercept Phase 3 program for wet AMD expected in calendar year (CY) Q2 2024 with top-line data mid-CY 2025
02/19 18:25 EST - globenewswire.com
Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor
Global retina expert joins to support sozinibercept development and launch preparation Global retina expert joins to support sozinibercept development and launch preparation
Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor
Global retina expert joins to support sozinibercept development and launch preparation Global retina expert joins to support sozinibercept development and launch preparation
02/14 07:00 EST - globenewswire.com
Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept
COAST trial is evaluating the superiority of sozinibercept combined with EYLEA ® (aflibercept) over EYLEA alone in wet AMD
Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept
COAST trial is evaluating the superiority of sozinibercept combined with EYLEA ® (aflibercept) over EYLEA alone in wet AMD
02/01 06:00 EST - globenewswire.com
Opthea Strengthens Team with Key Clinical and Regulatory Hires
Dr. Julie Clark, SVP Clinical Development; Dr. Fang Li, SVP Regulatory Affairs, to join February 1stExperienced executives bring extensive track record in products for retinal and ophthalmology diseases
Opthea Strengthens Team with Key Clinical and Regulatory Hires
Dr. Julie Clark, SVP Clinical Development; Dr. Fang Li, SVP Regulatory Affairs, to join February 1stExperienced executives bring extensive track record in products for retinal and ophthalmology diseases
12/27 06:00 EST - globenewswire.com
Opthea to Receive US$35M Commitment and Additional US$50M Funding
MELBOURNE, Australia, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that it expects to receive the remaining US$35 million committed funds under the Development Funding Agreement (DFA) with Carlyle and Abingworth, and has entered into binding documentation with a new co-investor under an Amended DFA to secure an additional US$50 million in funding.
Opthea to Receive US$35M Commitment and Additional US$50M Funding
MELBOURNE, Australia, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that it expects to receive the remaining US$35 million committed funds under the Development Funding Agreement (DFA) with Carlyle and Abingworth, and has entered into binding documentation with a new co-investor under an Amended DFA to secure an additional US$50 million in funding.
12/19 06:00 EST - globenewswire.com
Opthea Receives A$8.8 million R&D Tax Incentive
MELBOURNE, Australia, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that it has received an A$8.8 million (US$5.9 million) research and development (R&D) tax credit from the Australian Taxation Office. The cash incentive is for research and development costs incurred in the 2022/2023 financial year, and represents the amount disclosed in the company's audited financial statements at 30 June 2023.
Opthea Receives A$8.8 million R&D Tax Incentive
MELBOURNE, Australia, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that it has received an A$8.8 million (US$5.9 million) research and development (R&D) tax credit from the Australian Taxation Office. The cash incentive is for research and development costs incurred in the 2022/2023 financial year, and represents the amount disclosed in the company's audited financial statements at 30 June 2023.
12/01 05:30 EST - globenewswire.com
Opthea to Present at the FLORetina 2023 Congress
MELBOURNE, Australia, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced an oral presentation featuring sozinibercept (OPT-302) which will be presented at the annual FLORetina Congress being held November 30 to December 3, 2023, in Rome, Italy.
Opthea to Present at the FLORetina 2023 Congress
MELBOURNE, Australia, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced an oral presentation featuring sozinibercept (OPT-302) which will be presented at the annual FLORetina Congress being held November 30 to December 3, 2023, in Rome, Italy.
11/09 05:30 EST - GlobeNewsWire
Opthea to Present at the Jefferies 2023 London Healthcare Conference
MELBOURNE, Australia, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company's Founder and Chief Innovation Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference being held on November 14th -16th, 2023.
Opthea to Present at the Jefferies 2023 London Healthcare Conference
MELBOURNE, Australia, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company's Founder and Chief Innovation Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference being held on November 14th -16th, 2023.
10/30 05:30 EST - GlobeNewsWire
Opthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference
MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company's Founder & Chief Innovation Officer, will present at Eyecelerator which is part of AAO 2023 being held in San Francisco, CA on November 3rd to 6th, 2023.
Opthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference
MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company's Founder & Chief Innovation Officer, will present at Eyecelerator which is part of AAO 2023 being held in San Francisco, CA on November 3rd to 6th, 2023.
10/27 05:30 EST - globenewswire.com
Opthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFO
Dr. Megan Baldwin transitions to Founder, Chief Innovation Officer and remains on the Board of Directors
Opthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFO
Dr. Megan Baldwin transitions to Founder, Chief Innovation Officer and remains on the Board of Directors
10/02 05:30 EST - globenewswire.com
Opthea to Participate at the 2023 Euretina Congress
MELBOURNE, Australia, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that on October 4th, Dr. Megan Baldwin, the Company's Chief Executive Officer will be a panelist at the inaugural Euretina Innovation Spotlight forum which is part of the Organization's 23rd Congress being held on October 5th – 8th in Amsterdam, The Netherlands.
Opthea to Participate at the 2023 Euretina Congress
MELBOURNE, Australia, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that on October 4th, Dr. Megan Baldwin, the Company's Chief Executive Officer will be a panelist at the inaugural Euretina Innovation Spotlight forum which is part of the Organization's 23rd Congress being held on October 5th – 8th in Amsterdam, The Netherlands.
09/07 05:30 EST - globenewswire.com
Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference
MELBOURNE, Australia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Mr. Tim Morris, the Company's Chief Financial Officer will present at H.C. Wainwright's 25th Annual Global Investment Conference being held at the Lotte New York Palace Hotel in New York City on September 11th – 13th, 2023.
Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference
MELBOURNE, Australia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Mr. Tim Morris, the Company's Chief Financial Officer will present at H.C. Wainwright's 25th Annual Global Investment Conference being held at the Lotte New York Palace Hotel in New York City on September 11th – 13th, 2023.